Media stories about VERONA PHARMA P/S (NASDAQ:VRNA) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VERONA PHARMA P/S earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.2401021846939 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities analysts recently weighed in on VRNA shares. ValuEngine cut VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Zacks Investment Research cut VERONA PHARMA P/S from a “strong-buy” rating to a “hold” rating in a research report on Saturday. Wedbush set a $56.00 price objective on VERONA PHARMA P/S and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $26.00 price objective on shares of VERONA PHARMA P/S in a research report on Friday, August 10th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $31.33.
Shares of NASDAQ VRNA traded down $0.11 during trading hours on Monday, hitting $11.56. 526 shares of the company’s stock were exchanged, compared to its average volume of 2,847. VERONA PHARMA P/S has a 1-year low of $10.44 and a 1-year high of $25.55. The stock has a market capitalization of $153.19 million, a PE ratio of -4.80 and a beta of -2.86.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Story: NASDAQ
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.